These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 15323580

  • 1. Induction immunosuppression in kidney transplant recipients older than 60 years of age : safety and efficacy of ATGAM, OKT3 and Simulect.
    Heifets M, Saeed MI, Parikh MH, Sierka D, Kumar MS.
    Drugs Aging; 2004; 21(11):747-56. PubMed ID: 15323580
    [Abstract] [Full Text] [Related]

  • 2. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.
    Hill P, Cross NB, Barnett AN, Palmer SC, Webster AC.
    Cochrane Database Syst Rev; 2017 Jan 11; 1(1):CD004759. PubMed ID: 28073178
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection.
    Sollinger H, Kaplan B, Pescovitz MD, Philosophe B, Roza A, Brayman K, Somberg K.
    Transplantation; 2001 Dec 27; 72(12):1915-9. PubMed ID: 11773888
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era.
    Hariharan S, Alexander JW, Schroeder TJ, First MR.
    Clin Transplant; 1996 Apr 27; 10(2):186-90. PubMed ID: 8664516
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Use of basiliximab induction in low-immunological risk renal transplant recipients receiving tacrolimus-based immunosuppression.
    Gavela Martínez E, Avila Bernabeu AI, Sancho Calabuig A, Beltrán Catalán S, Escudero Quesada V, Pallardó Mateu LM.
    Transplant Proc; 2009 Apr 27; 41(6):2337-8. PubMed ID: 19715913
    [Abstract] [Full Text] [Related]

  • 12. Antibody induction therapy for lung transplant recipients.
    Penninga L, Møller CH, Penninga EI, Iversen M, Gluud C, Steinbrüchel DA.
    Cochrane Database Syst Rev; 2013 Nov 27; 2013(11):CD008927. PubMed ID: 24282128
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cadaveric kidney transplantation under prophylactic polyclonal antibody immunosuppression with anti-lymphoblast globulin versus anti-thymocyte globulin.
    Indudhara R, Novick AC, Hodge E, Goormastic M, Papajcik D, Mastroianni B, Cook D.
    Urology; 1996 Jun 27; 47(6):807-12. PubMed ID: 8677568
    [Abstract] [Full Text] [Related]

  • 15. Induction treatment with rabbit antithymocyte globulin versus basiliximab in renal transplant recipients with planned early steroid withdrawal.
    Martin ST, Roberts KL, Malek SK, Tullius SG, Vadivel N, De Serres S, Grafals M, Elsanjak A, Filkins BA, Chandraker A, Gabardi S.
    Pharmacotherapy; 2011 Jun 27; 31(6):566-73. PubMed ID: 21923440
    [Abstract] [Full Text] [Related]

  • 16. Low-dose RATG with or without basiliximab in renal transplantation: a matched-cohort observational study.
    Gentile G, Somma C, Gennarini A, Mastroluca D, Rota G, Lacanna F, Locatelli B, Remuzzi G, Ruggenenti P.
    Am J Nephrol; 2015 Jun 27; 41(1):16-27. PubMed ID: 25612603
    [Abstract] [Full Text] [Related]

  • 17. Acute rejection risk in kidney transplant recipients on steroid-avoidance immunosuppression receiving induction with either antithymocyte globulin or basiliximab.
    Heilman RL, Reddy KS, Mazur MJ, Moss AA, Post DJ, Petrides S, Mulligan DC.
    Transplant Proc; 2006 Jun 27; 38(5):1307-13. PubMed ID: 16797289
    [Abstract] [Full Text] [Related]

  • 18. Prophylaxis of heart transplant rejection with either antithymocyte globulin-, Minnesota antilymphocyte globulin-, or an OKT3-based protocol.
    Ladowski JS, Dillon T, Schatzlein MH, Peterson AC, Deschner WP, Beatty L, Sullivan M, Scheeringa RH, Clark WR.
    J Cardiovasc Surg (Torino); 1993 Apr 27; 34(2):135-40. PubMed ID: 8320247
    [Abstract] [Full Text] [Related]

  • 19. A prospective randomized trial of OKT3 vs ATGAM induction therapy in pancreas transplant recipients.
    Stratta RJ, Taylor RJ, Weide LG, Sindhi R, Sudan D, Castaldo P, Cushing KA, Frisbie K, Radio SJ.
    Transplant Proc; 1996 Apr 27; 28(2):917-8. PubMed ID: 8623461
    [No Abstract] [Full Text] [Related]

  • 20. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
    Woodle ES, Bruce DS, Josephson M, Cronin D, Newell KA, Millis JM, Piper JB, O'Laughlin R, Thistlethwaite JR.
    Clin Transplant; 1996 Aug 27; 10(4):389-95. PubMed ID: 8884115
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.